Eduardo Barroso

Eduardo Barroso

Auto-generated profile, based on publicly available information

Eduardo Barroso

Serviço de Cirurgia Geral. Hospital de Curry Cabral. Centro Hospitalar de Lisboa Central. Lisboa. Portugal

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2011 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MJMechteld C de Jong
Mechteld C de Jong
HNHari Nathan
Hari Nathan
GSGeorgios C. Sotiropoulos
Georgios C. Sotiropoulos
APAndreas Paul
Andreas Paul
SASorin Alexandrescu
Sorin Alexandrescu
TPTimothy M. Pawlik
Timothy M. Pawlik
Purpose: To identify factors associated with outcome after surgical management of intrahepatic cholangiocarcinoma (ICC) and examine the impact of lymph node (LN) assessment on survival.Patients and Methods: From an international multi-institutional database, 449 patients who underwent surgery for ICC between 1973 and 2010 were identified. Clinical and pathologic data were evaluated using uni- and multivariate analyses.Results: Median tumor size was 6.5 cm. Most patients had a solitary tumor (73%) and no vascular invasion (69%). Median survival was 27 months, and 5-year survival was 31%. Factors associated with adverse prognosis included positive margin status (hazard ratio [HR], 2.20; P < .001), multiple lesions (HR, 1.80; P = .001), and vascular invasion (HR, 1.59; P = .015). Tumor size was not a prognostic factor (HR, 1.03; P = .23). Patients were stratified using the American Joint Committee on Cancer/International Union Against Cancer T1, T2a, and T2b categories (seventh edition) in a discrete step-wise fashion (P < .001). Lymphadenectomy was performed in 248 patients (55%); 74 of these (30%) had LN metastasis. LN metastasis was associated with worse outcome (median survival: N0, 30 months v N1, 24 months; P = .03). Although patients with no LN metastasis were able to be stratified by tumor number and vascular invasion (N0; P < .001), among patients with N1 disease, multiple tumors and vascular invasion, either alone or together, failed to discriminate patients into discrete prognostic groups (P = .34).Conclusion: Although tumor size provides no prognostic information, tumor number, vascular invasion, and LN metastasis were associated with survival. N1 status adversely affected overall survival and also influenced the relative effect of tumor number and vascular invasion on prognosis. Lymphadenectomy should be strongly considered for ICC, because up to 30% of patients will have LN metastasis.

1 May 2014 in JAMA Surgery
Verified
Journal Article
Open access
PDF file
OHOmar Hyder
Omar Hyder
HMHugo Pinto Marques
Hugo Pinto Marques
Carlo PulitanoCarlo Pulitano
Carlo Pulitano
JMJ. Wallis Marsh
J. Wallis Marsh
SASorin Alexandrescu
Sorin Alexandrescu
Tim PawlikTim Pawlik
Tim Pawlik
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver malignant tumor after hepatocellular carcinoma (HCC). It represents 10% to 20% of all primary liver malignant tumors, with an estimated 3100 new cases of ICC occurring every year in the United States.1 A relatively uncommon disease with a poor prognosis for survival, the incidence of ICC has been increasing during the last 3 decades.2,3 Surgical resection is the mainstay of curative intent treatment for ICC and is associated with improved survival in selected patients.2,3 We previously published data on a large, multi-institutional, multinational cohort of patients and noted that 5-year survival after surgical resection was 30% to 35%.3

1 September 2015 in Transplantation
Verified
Journal Article
Closed access
BEBo-Göran Ericzon
Bo-Göran Ericzon
HWHenryk E. Wilczek
Henryk E. Wilczek
MLMarie Larsson
Marie Larsson
Priyantha WijayatungaPriyantha Wijayatunga
Priyantha Wijayatunga
ASArie Stangou
Arie Stangou
OSOle Suhr
Ole Suhr
Background Until recently, liver transplantation (Ltx) was the only available treatment for hereditary transthyretin (TTR) amyloidosis; today, however, several pharmacotherapies are tested. Herein, we present survival data from the largest available database on transplanted hereditary TTR patients to serve as a base for comparison. Methods Liver transplantation was evaluated in a 20-year retrospective analysis of the Familial Amyloidosis Polyneuropathy World Transplant Registry. Results From April 1990 until December 2010, data were accumulated from 77 liver transplant centers. The Registry contains 1940 patients, and 1379 are alive. Eighty-eight Ltx were performed in combination with a heart and/or kidney transplantation. Overall, 20-year survival after Ltx was 55.3%. Multivariate analysis revealed modified body mass index, early onset of disease (<50 years of age), disease duration before Ltx, and TTR Val30Met versus non-TTR Val30Met mutations as independent significant survival factors. Early-onset patients had an expected mortality rate of 38% that of the late-onset group (P < 0.001). Furthermore, Val30Met patients had an expected mortality rate of 61% that of non-TTR Val30Met patients (P < 0.001). With each year of duration of disease before Ltx, expected mortality increased by 11% (P < 0.001). With each 100-unit increase in modified body mass index at Ltx, the expected mortality decreased to 89% of the expected mortality (P < 0.001). Cardiovascular death was markedly more common than that observed in patients undergoing Ltx for end-stage liver disease. Conclusions Long-term survival after Ltx, especially for early-onset TTR Val30Met patients, is excellent. The risk of delaying Ltx by testing alternative treatments, especially in early-onset TTR Val30Met patients, requires consideration.

1 June 2013 in Surgery
Verified
Journal Article
Closed access
OHOmar Hyder
Omar Hyder
IHIoannis Hatzaras
Ioannis Hatzaras
GSGeorgios C. Sotiropoulos
Georgios C. Sotiropoulos
APAndreas Paul
Andreas Paul
SASorin Alexandrescu
Sorin Alexandrescu
Tim PawlikTim Pawlik
Tim Pawlik

18 December 2013 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
Luca ViganòLuca Viganò
Luca Viganò
LCLorenzo Capussotti
Lorenzo Capussotti
RLRéal Lapointe
Réal Lapointe
EBEduardo Barroso
Eduardo Barroso
CHCatherine Hubert
Catherine Hubert
RARené Adam
René Adam

13 March 2012 in Cancer
Verified
Journal Article
Open access
PDF file
MJMechteld C de Jong
Mechteld C de Jong
HMHugo Pinto Marques
Hugo Pinto Marques
BCBryan M. Clary
Bryan M. Clary
TBTodd W. Bauer
Todd W. Bauer
JMJ. Wallis Marsh
J. Wallis Marsh
Tim PawlikTim Pawlik
Tim Pawlik
BACKGROUND. Surgical strategy for hilar cholangiocarcinoma often includes hepatectomy, but the role of portal vein resection (PVR) remains controversial. In this study, the authors sought to identify factors associated with outcome after surgical management of hilar cholangiocarcinoma and examined the impact of PVR on survival.METHODS: Three hundred five patients who underwent curative‐intent surgery for hilar cholangiocarcinoma between 1984 and 2010 were identified from an international, multi‐institutional database. Clinicopathologic data were evaluated using univariate and multivariate analyses.RESULTS: Most patients had hilar cholangiocarcinoma with tumors classified as T3/T4 (51.1%) and Bismuth‐Corlette type II/III (60.9%). Resection involved extrahepatic bile duct resection (EHBR) alone (26.6%); or hepatectomy and EHBR without PVR (56.7%); or combined hepatectomy, EHBR, and PVR (16.7%). Negative resection (R0) margin status was higher among the patients who underwent hepatectomy plus EHBR (without PVR, 64.2%; with PVR, 66.7%) versus EHBR alone (54.3%; P < .001). The median number of lymph nodes assessed was higher among the patients who underwent hepatectomy plus EHBR (without PVR, 6 lymph nodes; with PVR, 4 lymph nodes) versus EHBR alone (2 lymph nodes; P < .001). The 90‐day mortality rate was lower for patients who underwent EHBR alone (1.2%) compared with the rate for patients who underwent hepatectomy plus EHBR (without PVR, 10.6%, with PVR, 17.6%; P < .001). The overall 5‐year survival rate was 20.2%. Factors that were associated with an adverse prognosis included lymph node metastasis (hazard ratio [HR], 1.79; P = .002) and R1 margin status (HR, 1.81; P < .001). Microscopic vascular invasion did not influence survival (HR, 1.23; P = .19). Among the patients who underwent hepatectomy plus EHBR, PVR was not associated with a worse long‐term outcome (P = .76).CONCLUSIONS: EHBR alone was associated with a greater risk of positive surgical margins and worse lymph node clearance. The current results indicated that hepatectomy should be considered the standard treatment for hilar cholangiocarcinoma, and PVR should be undertaken when necessary to extirpate all disease. Combined hepatectomy, EHBR, and PVR can offer long‐term survival in some patients with advanced hilar cholangiocarcinoma. Cancer 2012. © 2012 American Cancer Society.